Skip to main content
C

CSPC Innovation Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 300765 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,349 across all filing types
Latest filing 2026-04-27 Proxy Solicitation & In…
Country CN China
Listing Shenzhen Stock Exchange 300765

About CSPC Innovation Pharmaceutical Co.,Ltd.

https://www.xnwpharma.net

CSPC Innovation Pharmaceutical Co., Ltd. focuses on the research, development, production, and distribution of pharmaceutical products and high-end chemical ingredients. The company is a leading global supplier of caffeine and related derivatives, serving the food, beverage, and pharmaceutical sectors. Its product portfolio includes finished dosage forms such as acarbose for the treatment of type 2 diabetes, as well as various functional health products and nutritional supplements. The organization emphasizes technological innovation and quality control in its manufacturing processes, maintaining large-scale production facilities that adhere to international standards. By leveraging advanced chemical synthesis and biotechnology, the company provides essential ingredients and therapeutic solutions to a diverse international clientele, positioning itself as a key player in the global supply chain for specialized pharmaceutical components.

Recent filings

Filing Released Lang Actions
上市公司独立董事候选人声明与承诺（周建平）
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a declaration and commitment by an independent director candidate (“独立董事候选人声明与承诺”) submitted by the nominee ahead of a board election. It details qualifications, legal compliance, and independence criteria required for shareholder voting. This type of material is part of the proxy solicitation/information statement provided to shareholders to inform and request votes on board director nominations, fitting the Proxy Solicitation & Information Statement (PSI) category rather than an announcement of an actual appointment or report publication.
2026-04-27 Chinese
独立董事提名人声明与承诺（周宏）
Regulatory Filings Classification · 1% confidence The document is a formal statement and commitment by the board nominating an independent director candidate, detailing compliance with legal and exchange rules. It does not announce an actual board change or appointment, nor does it contain full AGM materials or proxy solicitation language inviting votes. Instead it is a regulatory compliance statement filed to the Shenzhen Stock Exchange. It therefore falls under the general “Regulatory Filings” category (RNS) as a fallback for miscellaneous but required compliance disclosures.
2026-04-27 Chinese
2026年一季度报告
Interim / Quarterly Report Classification · 1% confidence The document is titled “2026年第一季度报告” and contains comprehensive first quarter financial statements—including balance sheet, income statement, cash flow statement—along with detailed management discussion and analysis. This matches an Interim/Quarterly Report, not merely an announcement or summary. Therefore, it falls under the Interim / Quarterly Report category (Code: IR). Q1 2026
2026-04-27 Chinese
独立董事提名人声明与承诺（李迪斌）
Board/Management Information Classification · 1% confidence The document is a formal public declaration and commitment by the company’s board nominating an independent director candidate. It concerns governance and composition of the board rather than financial results, legal proceedings, or proxy solicitations. This falls under announcements of changes related to the company’s board of directors. Therefore, it is classified as Board/Management Information (MANG).
2026-04-27 Chinese
关于使用部分闲置募集资金进行现金管理的进展公告
Regulatory Filings
2026-04-15 Chinese
关于控股子公司SYS6051注射液获得药物临床试验批准通知书的公告
Regulatory Filings
2026-04-15 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.